Canada orders 20 million more doses of Pfizer/BioNTech COVID-19 vaccine: PM
Reuters
Published Jan 12, 2021 11:58
OTTAWA (Reuters) - Canada has ordered an additional 20 million doses of Pfizer Inc (NYSE:PFE)'s coronavirus vaccine, Prime Minister Justin Trudeau said on Tuesday after provinces complained about inadequate supplies.
Trudeau told reporters that Ottawa now had agreements with Pfizer, which developed its vaccine with German partner BioNTech, and Moderna Inc for a total of 80 million doses of their COVID-19 vaccines to be delivered this year.
Canada, which had initially ordered 20 million doses of the Pfizer/BioNTech vaccine with an option for 56 million more, now has a firm deal for 40 million doses of the two-shot vaccines.
Canada's 10 provinces, which have responsibility for administering the vaccines, say supplies are being delivered far too slowly.
Trudeau said that between April and June, Canada would have enough doses for 20 million people. Canada's population is just over 38 million.
Trudeau also said Canada was extending an existing ban on non-essential travel with the United States until Feb 21. The measures, which do not apply to trade flows, were first imposed last March and have been regularly rolled over.
Get The App
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.